Last updated 5 days ago

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

1000 patients around the world
Available in Chile, Brazil, Argentina
Bristol-Myers Squibb
17Research sites
1000Patients around the world

This study is for people with

Lung cancer
Non-small cell lung carcinoma

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with tumor cell PD-L1 expression 1% to 49% as determined by a central laboratory.
Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
Participants must have no prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic disease.
Participants must not have epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy.
Participants must not have untreated central nervous system (CNS) metastases.
Participants must not have concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization.
Participants must not have an active autoimmune disease.
Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids.
Participants must not have a history of myocarditis, regardless of etiology.
Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
Other protocol-defined Inclusion/Exclusion criteria apply.

Sites

Hospital Privado de la Comunidad
Recruiting
Córdoba 4545, Mar del Plata, Buenos Aires
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Juan Domingo Perón 4190, Piso 1, Ciudad Autónoma de Buenos Aires, C1181ACH
Sanatorio Parque - Rosario
Recruiting
Boulevard Oroño 860, Rosario, Santa Fe
Hospital Privado de Córdoba
Recruiting
Naciones Unidas 346, Córdoba
Instituto Médico Río Cuarto
Recruiting
Hipólito Yrigoyen 1020, X5800 Río Cuarto, Córdoba, Argentina
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul
Recruiting
Av. Ipiranga, 6690 - 4º andar - Partenon, Porto Alegre - RS, 90610-001, Brazil
Catatina Pesquisa Clinica - Clinica de Neoplasias Litoral
Recruiting
Itajai, 88331-10
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Recruiting
Pr. da Cruz Vermelha, 23 - Centro, Rio de Janeiro - RJ, 20230-130
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy